Clinical Trials Logo

Raltitrexed clinical trials

View clinical trials related to Raltitrexed.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05426811 Not yet recruiting - Clinical trials for Colorectal Neoplasms

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Start date: July 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.